Thermo Fisher Scientific (TMO) Coverage Initiated at BTIG Research

BTIG Research started coverage on shares of Thermo Fisher Scientific (NYSE:TMO) in a research report report published on Friday morning, MarketBeat reports. The brokerage issued a buy rating and a $230.00 target price on the medical research company’s stock.

Several other research firms have also recently commented on TMO. Deutsche Bank set a $226.00 target price on shares of Thermo Fisher Scientific and gave the stock a buy rating in a research report on Thursday, October 26th. Zacks Investment Research cut shares of Thermo Fisher Scientific from a buy rating to a hold rating in a research report on Tuesday, September 12th. Leerink Swann lifted their target price on shares of Thermo Fisher Scientific from $190.00 to $207.00 and gave the stock an outperform rating in a research report on Monday, October 9th. Evercore ISI began coverage on shares of Thermo Fisher Scientific in a research report on Wednesday, January 3rd. They set an outperform rating and a $220.00 target price on the stock. Finally, Cowen reissued an outperform rating and set a $220.00 target price (up previously from $200.00) on shares of Thermo Fisher Scientific in a research report on Sunday, September 10th. One research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. The stock presently has an average rating of Buy and a consensus target price of $212.21.

Thermo Fisher Scientific (NYSE TMO) traded up $3.41 during trading on Friday, hitting $202.39. 1,469,400 shares of the company’s stock traded hands, compared to its average volume of 1,408,700. Thermo Fisher Scientific has a 1 year low of $140.00 and a 1 year high of $202.65. The company has a debt-to-equity ratio of 0.85, a quick ratio of 0.81 and a current ratio of 1.26. The company has a market cap of $80,600.00, a PE ratio of 34.36, a P/E/G ratio of 1.65 and a beta of 1.06.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, October 25th. The medical research company reported $2.31 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.24 by $0.07. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. The firm had revenue of $5.12 billion for the quarter, compared to analysts’ expectations of $5.03 billion. During the same quarter last year, the firm earned $2.03 EPS. The company’s quarterly revenue was up 13.9% compared to the same quarter last year. sell-side analysts expect that Thermo Fisher Scientific will post 9.36 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Monday, January 15th. Investors of record on Friday, December 15th will be issued a $0.15 dividend. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.30%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.19%.

In related news, CEO Marc N. Casper sold 50,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $191.74, for a total value of $9,587,000.00. Following the sale, the chief executive officer now owns 302,577 shares of the company’s stock, valued at approximately $58,016,113.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.49% of the company’s stock.

A number of hedge funds have recently modified their holdings of the business. Abner Herrman & Brock LLC raised its holdings in Thermo Fisher Scientific by 10.9% during the 4th quarter. Abner Herrman & Brock LLC now owns 32,190 shares of the medical research company’s stock valued at $6,112,000 after acquiring an additional 3,159 shares during the period. Washington Trust Bank raised its holdings in Thermo Fisher Scientific by 6.7% during the 4th quarter. Washington Trust Bank now owns 34,032 shares of the medical research company’s stock valued at $6,462,000 after acquiring an additional 2,143 shares during the period. Neville Rodie & Shaw Inc. raised its holdings in Thermo Fisher Scientific by 1.6% during the 4th quarter. Neville Rodie & Shaw Inc. now owns 113,255 shares of the medical research company’s stock valued at $21,505,000 after acquiring an additional 1,772 shares during the period. Atlantic Trust Group LLC raised its holdings in Thermo Fisher Scientific by 25.6% during the 3rd quarter. Atlantic Trust Group LLC now owns 710,772 shares of the medical research company’s stock valued at $134,480,000 after acquiring an additional 144,924 shares during the period. Finally, AustralianSuper Pty Ltd raised its holdings in Thermo Fisher Scientific by 73.6% during the 3rd quarter. AustralianSuper Pty Ltd now owns 689,898 shares of the medical research company’s stock valued at $130,529,000 after acquiring an additional 292,398 shares during the period. 86.22% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This piece was reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.com-unik.info/2018/01/08/thermo-fisher-scientific-tmo-coverage-initiated-at-btig-research.html.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Analyst Recommendations for Thermo Fisher Scientific (NYSE:TMO)

What are top analysts saying about Thermo Fisher Scientific? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Thermo Fisher Scientific and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit